Procoralan: new option for chronic heart failure

Procoralan (ivabradine) can now be prescribed for the treatment of chronic heart failure as an addition to standard therapy.

Procoralan is also licensed for the treatment of chronic stable angina
Procoralan is also licensed for the treatment of chronic stable angina
The double-blind SHIFT study compared ivabradine, the only licensed sinus node If inhibitor, with placebo in patients with stable chronic heart failure (NHYA class II to IV). Patients were randomised to receive ivabradine 7.5mg twice daily (n=3268) or placebo (n=3290), and were permitted to continue stable background therapy (including β-blockers) if tolerated. Investigators used a composite of cardiovascular death or hospital admission for worsening heart failure as the primary endpoint, and all analyses were based on the intention to treat population.

At the end of the follow-up period (median 22.9 months), fewer patients met the primary endpoint in the ivabradine group (793 events) than in the control group (937 events), resulting in a hazard ratio of 0.82 (95% CI 0.75-0.90; p<0.0001).

View Procoralan drug record

Further information: Servier Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

MST Continus granules to be discontinued

MST Continus granules to be discontinued

All strengths of MST Continus (morphine) prolonged-release...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...